Your browser is no longer supported. Please, upgrade your browser.
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.37 Insider Own1.10% Shs Outstand43.40M Perf Week12.63%
Market Cap239.14M Forward P/E- EPS next Y-0.30 Insider Trans0.00% Shs Float39.81M Perf Month-17.69%
Income-15.90M PEG- EPS next Q0.05 Inst Own45.40% Short Float3.42% Perf Quarter-39.96%
Sales44.30M P/S5.40 EPS this Y66.20% Inst Trans4.37% Short Ratio5.48 Perf Half Y-35.39%
Book/sh1.63 P/B3.28 EPS next Y81.60% ROA-17.20% Target Price12.50 Perf Year-34.95%
Cash/sh1.36 P/C3.92 EPS next 5Y- ROE-21.10% 52W Range4.45 - 11.68 Perf YTD-32.87%
Dividend- P/FCF- EPS past 5Y11.90% ROI-11.70% 52W High-54.21% Beta0.31
Dividend %- Quick Ratio6.20 Sales past 5Y53.60% Gross Margin76.40% 52W Low20.22% ATR0.30
Employees195 Current Ratio6.60 Sales Q/Q-6.70% Oper. Margin-35.50% RSI (14)46.60 Volatility6.84% 5.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-631.20% Profit Margin-35.90% Rel Volume0.36 Prev Close5.18
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume248.41K Price5.35
Recom1.60 SMA20-1.51% SMA50-12.85% SMA200-31.63% Volume88,957 Change3.28%
Oct-14-21Resumed B. Riley Securities Buy $10
Sep-17-20Initiated Jefferies Buy $15
Sep-01-20Initiated SVB Leerink Outperform $15
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
Nov-15-21 04:30PM  
Nov-04-21 04:15PM  
Oct-20-21 07:05AM  
Oct-14-21 07:13AM  
Oct-13-21 07:27AM  
Oct-12-21 04:38PM  
Oct-07-21 03:11PM  
Sep-14-21 09:25AM  
Sep-13-21 07:08AM  
Sep-10-21 07:08AM  
Sep-08-21 04:15PM  
Sep-01-21 09:26AM  
Aug-30-21 11:57AM  
Aug-12-21 07:03AM  
Aug-04-21 07:00AM  
Aug-03-21 04:15PM  
Jul-30-21 07:08AM  
Jul-19-21 07:08AM  
Jul-06-21 04:37PM  
Jun-28-21 03:30AM  
Jun-01-21 07:08AM  
May-27-21 07:00AM  
May-25-21 07:08AM  
May-23-21 04:11AM  
May-19-21 07:00AM  
May-11-21 03:30PM  
May-04-21 04:15PM  
Apr-27-21 01:55PM  
Apr-19-21 12:22PM  
Apr-17-21 03:49AM  
Mar-29-21 07:08AM  
Mar-16-21 03:15PM  
Mar-12-21 07:00AM  
Mar-09-21 04:28PM  
Mar-08-21 10:10AM  
Mar-02-21 07:00AM  
Mar-01-21 06:00PM  
Feb-24-21 07:08AM  
Feb-18-21 07:08AM  
Feb-16-21 07:08AM  
Feb-04-21 07:08AM  
Jan-26-21 01:02AM  
Jan-21-21 07:08AM  
Jan-19-21 07:08AM  
Jan-12-21 07:00AM  
Jan-11-21 06:00AM  
Jan-04-21 06:30AM  
Dec-17-20 07:08AM  
Dec-13-20 09:44PM  
Dec-10-20 07:00AM  
Dec-09-20 06:45AM  
Dec-02-20 07:08AM  
Nov-25-20 07:08AM  
Nov-23-20 07:00AM  
Nov-12-20 02:00AM  
Nov-10-20 05:25AM  
Nov-06-20 06:05AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-21-20 07:08AM  
Oct-14-20 07:00AM  
Oct-09-20 07:08AM  
Sep-21-20 07:08AM  
Sep-19-20 10:45AM  
Sep-11-20 08:00AM  
Sep-08-20 07:08AM  
Sep-01-20 04:50PM  
Aug-24-20 07:00AM  
Aug-17-20 07:08AM  
Aug-06-20 09:05AM  
Aug-05-20 09:01AM  
Aug-04-20 05:18PM  
Aug-03-20 12:47PM  
Jul-31-20 07:08AM  
Jul-28-20 07:08AM  
Jul-22-20 12:31PM  
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLOCH KATHLEEN P.Chief Financial OfficerNov 23Buy4.984,00019,92025,000Nov 26 06:11 PM
Kraus AlDirectorAug 31Option Exercise4.124,00016,500129,046Sep 02 04:31 PM
Kraus AlDirectorAug 31Sale9.404,00037,591125,046Sep 02 04:31 PM
BLOCH KATHLEEN P.Chief Financial OfficerDec 31Option Exercise5.607,85743,999333,013Jan 04 04:30 PM